The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.

Nallasivam PalanisamyJun YangPeter D A ShepherdElsa M Li-Ning-Tapia Estefanía LabancaGaniraju C ManyamMurali K RavooriVikas KundraJohn C AraujoEleni EfstathiouLouis L PistersXinhai WanXuemei WangElba S Vazquez Ana M AparicioShannon L CarskadonScott A TomlinsLakshmi P KunjuArul M ChinnaiyanBradley M BroomChristopher J LogothetisPatricia TroncosoNora M Navone

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

The MDA PCa PDX series is a dynamic resource that captures the molecular landscape of prostate cancers progressing under novel treatments and enables optimization of prostate cancer-specific, marker-driven therapy.

Keyphrases

prostate cancer
radical prostatectomy
breast cancer cells
single cell
single molecule
molecular dynamics
cell death
mesenchymal stem cells
cell cycle arrest